Aspira Women’s Health Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $2.4 million, a slight decrease of 1% from $2.4 million in the same period of 2024. For the first half of 2025, revenue increased by 2% to $4.7 million compared to $4.6 million in the prior year. The company experienced a net loss of $2.7 million for the quarter, an improvement from a loss of $3.5 million in the previous year, and a net loss of $4.5 million for the six months ended June 30, 2025, compared to a loss of $8.2 million in the same period of 2024.
The company’s operational metrics showed a decline in the number of OvaSuite tests performed, which fell by 11% to 5,728 tests in the second quarter of 2025, down from 6,471 tests in the same quarter of 2024. This decrease was attributed to a reduction in field sales personnel. However, the average unit price (AUP) for Ova1Plus and OvaWatch tests increased, contributing to the overall revenue stability. The gross profit margin improved to 63.8% for the quarter, up from 58.6% in the prior year, reflecting a decrease in the cost of revenue, which fell by 13% to $870,000.
Strategically, Aspira has been focusing on enhancing its product offerings and expanding its market reach. The company has entered into new distribution agreements, including an expanded partnership with BioReference Health, which will allow for broader access to its OvaWatch test. Additionally, the company is actively working on the development of new diagnostic tests, including ENDOinform for endometriosis, which is expected to tap into a larger addressable market.
Despite these developments, Aspira faces significant financial challenges, including an accumulated deficit of approximately $535.9 million as of June 30, 2025. The company reported cash and cash equivalents of $1.5 million, with current liabilities totaling $4.1 million, indicating a working capital deficit. Aspira has indicated that it may need to raise additional capital through equity offerings or other financing methods to sustain its operations and continue its growth trajectory. The company has expressed uncertainty about its ability to achieve profitability or positive cash flow in the near future, emphasizing the need for strategic financial management moving forward.
About Aspira Women's Health Inc.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.